Manufacturers report bemarituzumab effective for first line advanced gastric and gastroesophageal junction cancer

In the Phase 2 FIGHT trial, this antibody targeting FGFR2b+ tumours demonstrated significant overall survival benefit compared to placebo plus chemotherapy (improved from 12.9 months vs not reached, HR 0.58,95% CI: 0.35-0.95; p=0.027).

Biospace Inc.